Loading the company…
Loading the company…
Families: Dialysis access, Cholecystectomy & appendectomy, Mechanical circulatory support.
All companies · Product and company coverage
In 2025, Maquet Cardiovascular reported engagement with 82 surgeons and other clinicians in the states MedaRep covers, worth $114K in consulting, speaking, meals and travel for its device products, the most in Wisconsin ($84K to 3). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Wisconsin ($84K, 3 engaged), California ($6,885, 11 engaged), Illinois ($3,537, 10 engaged), Texas ($3,536, 8 engaged), Florida ($2,961, 6 engaged).
In the last ten years FDA made 2 decisions for Maquet Cardiovascular (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 2 procedure families, the most in 2026 (1). The latest was on 2026-04-27.
| Family | Decisions on record |
|---|---|
| Dialysis access | 14 |
| Cholecystectomy & appendectomy | 1 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-04-27 | 510(k) | K252445 | Fusion Bioline Vascular Graft |
| 2020-04-15 | 510(k) | K191930 | 7 mm Extended Length Endoscope |
| 2016-02-16 | 510(k) | K153523 | FUSION Vascular Graft |
| 2013-11-14 | 510(k) | K131778 | FUSION VASCULAR GRAFT AND FUSION BIOLINE VASCULAR GRAFT |
| 1993-05-17 | PMA | P840029-S014 |
| HEMASHIELD(R) MICROVEL (R) DOUBLE VELOUR GRAFT · Change Design/Components/Specifications/Material |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Maquet Cardiovascular.